For the Inventor, By the Inventor

Enter inventor name

Dan Peters

USPTO Granted Patents = 115 (Patent Applications = 68)

Average Co-Inventor Count = 4.2

ph-index = 10

Forward Citations = 274(Granted Patents)

Forward Citations (Not Self Cited) = 240(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Arlöv, DK (2001)
Arlöv, SE (2002 - 2003)
Sverige, SE (2003)
Arlov, SE (1999 - 2005)
Ärlöv, SE (2004 - 2007)
Malmø, SE (2003 - 2009)
Balleup, DK (2009 - 2011)
Ballerup, DK (2007 - 2012)
Malmo, CH (2012)
Malmoe, SE (2007 - 2013)
Malmo, SE (1994 - 2015)
Malmö, SE (2007 - 2015)
Malmö, DK (2009 - 2016)

Company Filing History:

Neurosearch A/s

5. 1 out of 4,179

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 1994-2016

Loading Chart...

Areas of Expertise:

Purinyl Derivatives

Monoamine Neurotransmitter Re-Uptake Inhibitors

Potassium Channel Modulators

Nicotinic Acetylcholine Receptor Modulators

Oxadiazole Compounds

Cholinergic Receptor Modulators

Indolyl Derivatives

Pyrazolyl-Pyrimidine Derivatives

Amino-Pyridine Derivatives

Bicyclic Compounds

Triazole Derivatives

Small-Conductance Calcium-Activated Potassium Channels

115 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9340544 - Purinyl derivatives and their use as potassium channel modulators (2016-05-17),

2. 9133184 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2015-09-15),

3. 8986654 - Labelled and un-labelled methyl-pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use (2015-03-24),

4. 8946412 - Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators (2015-02-03),

5. 8778928 - Indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use (2014-07-15),

6. 8697721 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2014-04-15),

7. 8633218 - 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2014-01-21),

8. 8618099 - Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators (2013-12-31),

9. 8415358 - Pyrazine derivatives and their use as potassium channel modulators (2013-04-09),

10. 8410271 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2013-04-02),

11. 8372832 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use (2013-02-12),

12. 8362024 - Purinyl derivatives and their use as potassium channel modulators (2013-01-29),

13. 8343960 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use (2013-01-01),

14. 8268838 - Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators (2012-09-18),

15. 8263617 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-09-11),

Title: Dan Peters - Innovative Inventor from Malmö

Introduction: Dan Peters is a renowned inventor based in Malmö, Sweden, known for his groundbreaking contributions to various industries.

Latest Patents: Dan Peters holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Dan Peters has worked with leading research institutions and companies to bring his inventions to life. His commitment to pushing the boundaries of technology has earned him recognition in the global innovation community.

Collaborations: Throughout his career, Dan Peters has collaborated with top universities, research institutions, and multinational companies to develop cutting-edge solutions that address complex challenges in today's society.

Conclusion: Dan Peters' passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs. His impact on the world of inventions is truly remarkable.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…